New drug TS-172 tested in patients with liver impairment

NCT ID NCT07231029

Recruiting now Knowledge-focused Sponsor: Taisho Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing how the drug TS-172 behaves in the bodies of people with mild or moderate liver impairment. Researchers will measure drug levels in the blood to see if liver function affects how the drug is processed. The study involves 24 Japanese adults and is currently recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TS-172

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Taisho Pharmaceutical Co., Ltd selected site
RECRUITING

Tokyo, Japan

Contact Phone: •••-•••-•••• Email: •••••@•••••